In case of 10 patients adverse events occurred during DAA therapy and follow-up (Table S2), including portal vein thrombosis with liver failure, ascites, severe bacterial infections, vasculitis, nephropathy, monoclonal gammopathy, lymphomas and rapidly elevating ALT after treatment (Table S2). The gene discussed is GPT; the disease is vasculitis.